Board of Directors
Timothy C. Moynahan is the CEO and owner of Moynahan Partners. He founded the Moynahan Law Firm, Waterbury, Connecticut, and is a sought after and successful trial lawyer, earning the Super Lawyer of New England and Connecticut awards from 2009 to 2012 and Best Criminal Defense Attorney accolade in 2013. Mr. Moynahan seeks to improve his community through social, health, and education works. He founded and chairs the Global Virus Network (GVN). He is also a member of the Advisory Board and Executive Committee of the Institute of Human Virology, Vice President/Partner of Paula Moynahan M.D. Skin Care, member of the Post University MBA Advisory Council, and Attorney Emeritus for the Let’s Think Kids Foundation. He was a member of the Dean’s Council, School of Law, Quinnipiac University, and was a discussant on global business practice in Cyprus for the Southern Connecticut State University. Prior to this, Mr. Moynahan founded and chaired The Palace Theatre to preserve the cultural icon. Mr. Moynahan is President of the Ireland Chamber of Commerce in Connecticut. He has served as an advisor for the NBA Retired Players Association as Board member for the Leukemia Lymphoma Society, and chaired events for the Ataxia Telangiectasia Foundation, and the Order of the Sons of Italy. Post University inducted Mr. Moynahan into its Hall of Fame, named The Timothy C. Moynahan Law Library in his honor and awarded him a Doctor of Letters degree.
Mr. Arbess is multi-asset class investor, lawyer and social entrepreneur whose 35-year career has been defined by purposeful enagement as an adviser and investor in important global developments, most recently through his $3.5 Billion Xerion Hedge Funds. His focus in recent years has been on supporting healthcare stakeholders’ adaptation to the data and technology-rich environment of personalized/precision diagnostics, therapeutics and drug development. Dan served on the steering committee of the MIT/UCSB Alzheimer’s X initiative and is presently serving on the finance working group of the American Medical Association/One Mind Healthy Brain Global Initiative, and the Corporate Advisory Board of Cancer Expert Now.
He is a U.S. citizen born in Montreal, Canada; received his LLB from Osgoode Hall Law School (Toronto) and LLM from the Harvard Law School. He has been an affiliate at Harvard’s John F. Kennedy School of Government; is lifetime member Council on Foreign Relations and co-Founder, No Labels (advancing bipartisan Congressional collaboration). Dan is a frequent media commentator on political and economic developments.
Lawrence Blatt, Ph.D. is responsible for co-leading the Infectious Diseases & Vaccines (IDV) Therapeutic Area at Janssen Research & Development. Prior to joining the Johnson & Johnson Family of Companies, Lawrence founded and was President and Chief Executive Officer of Alios BioPharma, Inc., the clinical stage biopharmaceutical company focused on developing therapies for viral diseases that was acquired by Johnson & Johnson in 2014. He was named as key inventor on several Alios patents and won the 2012 Ernst & Young Entrepreneur of the Year Award for Life Sciences. Lawrence spent 30 years in pharmaceutical R&D with a specific focus on the biology of the immune system, antiviral therapies and relevant therapeutic interventions. Before forming Alios, he was Chief Scientific Officer of InterMune, Inc. where he led the discovery and development of an HCV protease inhibitor partnered with Roche. From 1998 to 2002, Lawrence was Vice President of Research at SIRNA. From 1996 to 1998, he served as Vice President, Product Development at National Genetics Institute where he pioneered the use of molecular diagnostics to drive therapeutic treatment decisions for viral infections. He began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for a consensus interferon product leading to approval by the United States Food and Drug Administration (FDA). Lawrence earned his B.S. in Microbiology from Indiana University, a Master’s in Business Administration at the California State University, Northridge, and a Doctorate in Public Health Administration at the University of La Verne, California.
Marc Bonneville, D.V.M. and CNRS research director, is from July 2020 onwards the Scientific and Medical director and deputy General Manager of Fondation Mérieux.
Marc started to work in 1983 on transplantation immunology in Nantes (France), switched from 1987 to 1989 to analysis of mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). He became in 1990 the principal investigator of a research team within an INSERM unit in Nantes, and took over the direction of this unit in 1995 for more than 15 years. In 2013, he was appointed as Chief Scientific and Medical Officer of the Institut Merieux, a biopharmaceutical holding that gathers companies developing diagnostic and therapeutic tools in the field of infectious diseases, cancer and food safety. Since 2016, he has been the chairman of the Alliance for Research and Innovation of Healthcare Industries (ARIIS), an organization which aims at fostering partnerships between public research and industries in the field of pharmaceuticals, medical devices and diagnostics. While pursuing non-profit activities within the Institut Mérieux, in particular the Young Investigator Award program that he launched in 2016, Marc has taken over in 2020 the position of scientific and medical director of the Fondation Mérieux, a non-profit entity that helps the most vulnerable countries and communities to fight infectious diseases through diagnostic and research capacity building.
Marc has authored more than 200 scientific papers, is co-inventor of 8 patents, and a co-founder of Innate Pharma SA, a biotech company that implements new immunotherapies targeting innate lymphocytes in infectiology and oncology. He has been involved in more than 30 national and international scientific advisory boards and evaluation committees. He has received the CNRS bronze and silver medals, and several prizes from charities (Fondation pour la Recherche Medicale, Ligue Nationale contre le Cancer, B. Halpern prize…) for his work on human cellular immunity in the context of infections and cancer.
Tomas Cihlar is a Vice President of Virology at Gilead Sciences with responsibility for coordinating preclinical antiviral research including projects on treatment, prevention, and cure of HIV, chronic hepatitis B, respiratory viruses, and emerging viruses. Tomas joined Gilead after receiving his PhD in Biochemistry from the Institute of Organic Chemistry and Biochemistry in Prague, Czechia. Over the years, he has contributed to the development and regulatory approval of multiple products including all Gilead’s antiretrovirals and their combinations. Together with his colleagues, he established research programs focused on long-acting antiretrovirals, in addition to a portfolio of projects aiming at the cure of HIV and hepatitis B, and programs on the treatment of respiratory and emerging/neglected viruses. Tomas has led multiple antiviral programs at Gilead including the first long-acting HIV capsid inhibitor as well as the broad-spectrum antiviral agent remdesivir that has progressed into clinical testing against Ebola virus and more recently against COVID-19. In 2006, Tomas received William Prusoff Young Investigator Award from the International Society for Antiviral Research (ISAR) and later on served on the ISAR Board of Directors.
Co-founder & Scientific Director, Global Virus Network.
The Institute of Human Virology (IHV) was co-founded and is directed by Robert C. Gallo, MD, the eminent scientist who became world famous in 1984 when he co-discovered HIV as the cause of AIDS. Little was known then of the mysterious disease that was fast becoming the deadliest in medical history. Since, Dr. Gallo has spent much of his career trying to put an end to this raging epidemic and other viral, chronic illnesses.
Though best known for his co-discovery of HIV, Gallo and his team pioneered the development of the HIV blood test, which enabled health care workers for the first time to screen for the AIDS virus – leading to a more rapid diagnosis while simultaneously protecting patients receiving blood transfusions. His research also helped physicians develop HIV therapies to prolong the lives of those infected with the virus. In 1996, his discovery that a natural compound known as chemokines can block HIV and halt the progression of AIDS was hailed by Science magazine as one of that year’s most important scientific breakthroughs. This also helped others identify CCR5 as the HIV co-receptor since these chemokines were known to bind to CCR5.
Prior to the AIDS epidemic, Gallo was the first to identify a human retrovirus and the only known human leukemia virus – HTLV – one of few known viruses shown to cause a human cancer. In 1976, he and his colleagues discovered Interleukin-2, a growth regulating substance now used as therapy in some cancers and sometimes AIDS. And in 1986, he and his group discovered the first new human herpes virus in more than 25 years (HHV-6), which was later shown to cause an infantile disease known as Roseola and currently is hypothesized as a strong suspect in the origin of multiple sclerosis.
Today, Dr. Gallo’s work continues at the IHV, a first-of-its-kind virology center that combines the disciplines of research, patient care and prevention programs in a concerted effort to speed the pace of medical breakthroughs. In addition to Dr. Gallo, IHV was also co-founded by William Blattner, MD, retired since 2016 and formerly associate director of the IHV and director of IHV’s Division of Epidemiology and Prevention and Robert Redfield, MD, associate director of the IHV and director of IHV’s Division of Clinical Care and Research. IHV is also comprised of a Basic Science Division, Vaccine Research Division, Immunotherapy Division, and four Scientific Core Facilities. The Institute is a part of the University of Maryland School of Medicine and affiliated with the University of Maryland Medical Center. IHV’s patient base includes approximately 6,000 in Baltimore and Washington, D.C., and more than 1.3 million in African and Caribbean nations. In particular, IHV is internationally renowned for its basic science and vaccine research, which includes a preventive HIV vaccine candidate in human clinical trials and funded largely by the Bill & Melinda Gates Foundation.
Additionally, in 2011 Dr. Gallo co-founded the Global Virus Network (GVN) to position the world to rapidly respond to new or re-emerging viruses that threaten mankind, to bring together and achieve collaboration amongst the world’s leading virologists, and to support training of the next generation of medical virologists.
Prior to becoming director of the Institute in 1996, Dr. Gallo spent 30 years at the National Institutes of Health’s National Cancer Institute, where he was head of its Laboratory of Tumor Cell Biology. A Connecticut native, his interest in science and medicine was first stirred by the loss of his 6-year-old sister to leukemia when he was just 12 years old. The physicians who cared for her made a lasting impression and Gallo would later make scientific research – and the opportunity to help put an end to deadly diseases – his life’s work.
Lifetime achievements in Dr. Gallo’s legendary career include discoveries that have led to both diagnostic and therapeutic advances in cancer, AIDS and other viral disorders while his vision remains unprecedented in the field of virology.
Dr. Gallo’s research has brought him international recognition as well as election into the National Academy of Sciences and the Institute of Medicine. He has been awarded honors for his contribution to science from countries around the world and holds 35 honorary doctorates. Dr. Gallo was the most referenced scientist in the world in the 1980s and 1990s, during which he had the unique distinction of twice winning America’s most prestigious scientific award – the Albert Lasker Award in Medicine – in 1982 and again in 1986. Dr. Gallo is the author of more than 1,200 scientific publications and the book “Virus Hunting – AIDS, Cancer & the Human Retrovirus: A Story of Scientific Discovery.”
Mathew L. Evins, Chairman and CEO of Evins, Ltd.
Mr. Evins has served as Chairman and CEO of Evins, Ltd., a leading branding, marketing, communications and public relations firm since 1987. Mr. Evins previously served as CEO of Pain Therapeutics Corporation, which was engaged in developing innovative methods for the diagnosis, treatment, and abatement of chronic pain, and copublished “The Talisman Report,” the world’s leading investment advisory newsletter for the three years of its publication. For more than ten years, Mr. Evins served on the staff of Cornell Medical Center, initially as a Surgical Research Associate in the Cardiovascular Research Laboratory and, subsequently, as Associate Director of The Rogosin Organ Retrieval & Preservation Laboratory. Mr. Evins is a member of the Board of Directors of Hommage Inc., as well as a founding member, Treasurer and a member of the Executive Committee of the Board of directors of the Global Virus Network.
William “Billy” Hall, GVN-Co-Founder, is the Director of the Centre for Research in Infectious Diseases (CRID) and Professor in the School of Medicine and Medical Science at University College Dublin. Professor Hall’s research interests are primarily on blood-borne viruses which include the human retroviruses, the human T lymphotropic viruses (HTLVs) and human immunodeficiency viruses (HIVs). Professor HaII has also recently established high profile collaboration with the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, Vietnam to carry out epidemiological studies on HIV and Hepatitis Band C virus infections in that country. Professor Hall is presently Chairman of the Technical Advisory Group of Irish Government Department of Foreign Affairs official aid program, Irish Aid. This group advises Irish Aid on the use of resources to combat HIV/AIDS and other communicable diseases. He has been a Director of the Atlantic Philanthropies since 2008.
Lan Kennedy-Davis’ legal practice focuses on general and complex litigation and corporate transactions, including business and shareholder matters, intellectual property disputes, bankruptcy litigation and high stakes and assets family law cases. She has a strong business background, is an economist, as well as former business consultant to Fortune 500 companies. She has served as Chief Legal Officer of a $800 million publicly traded company, CEO of a groundbreaking headphones company, Counsel to a $62 billion conglomerate and External General Counsel for over 30 private and publicly traded companies. Her clients include professional artists and athletes. Her eminent career is punctuated by important national and international legal victories that removed barriers, protected brands, defended company practices and enabled up to hundreds of millions of dollars in added revenues for her clients.
Dr. Liu was on faculty in a number of academic institutions across US, including New York University, the Ohio State University, University of Michigan, Children’s National Medical Center and most recently as Director of Division of Immunotherapy, Institute of Human Virology and Professor of Surgery, University of Maryland Baltimore School of Medicine. Dr. Liu’s academic research has been on the fundamental mechanisms of immune recognition, cell metabolism and cancer biology. Dr. Liu has been a driving force in elucidating the mechanisms by which the innate immune system discriminates microbial infection and aseptic tissue injuries. He was elected as AAAS fellow in 2004.
Dr. Yang Liu, Ph.D. was a co-founder of OncoImmune, Inc. and served as its Chairman, Chief Executive Officer and Chief Scientific Officer since 2000 until its acquisition by Merck, Inc. He continues to serves on the same position for OncoC4, Inc., a spin-off of OncoImmune, Inc. Dr. Liu has guided OncoImmune’s effort to translate breakthrough discoveries by the laboratories of Yang Liu and Pan Zheng, including most recently establishing strong therapeutic efficacy of CD24Fc for hospitalized severe and critical COVID-19 patients.
Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world (e.g., Indonesia, Malaysia, and Vietnam). He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent. Dr. Moore represented the HHS in cooperative international efforts with African nations in addressing continued health and human resources issues.
Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute (now Tuskegee University); his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
An educator, physician, and administrator during a distinguished career spanning more than 30 years, Dr. G. Richard Olds is President of St. George’s University in Grenada West Indies on August 28, 2015. Prior to joining SGU, he was the Vice Chancellor for Health Affairs and Founding Dean of the School of Medicine at the University of California, Riverside (UCR). In 2010, Dr. Olds joined UCR to lead the creation of a new school of medicine – the first LCME-accredited medical school in California in more than four decades.
Dr. Olds is a graduate of Case Western Reserve University School of Medicine and trained in internal medicine at the Massachusetts General Hospital in Boston. He was an infectious disease fellow and one of the nation’s first geographic medicine fellows at University Hospitals of Cleveland, where he also served as medical chief resident and faculty member. He served as full professor of medicine, pediatrics, molecular, cell and development biology at Brown University. He was also the founding Director on Brown’s International Health Institute. He was professor and chairman of medicine at the MetroHealth Campus of Case Western Reserve University in the 1990’s. His role at UCR was preceded by a decade long stint as professor and chair of medicine at the Medical College of Wisconsin. In addition to his academic background, Dr. Olds is a tropical disease specialist with extensive experience working in Asia and Africa. He has over 100 peer reviewed articles and book chapters primarily on international health topics. He was the Foreign Principal Investigator of an NIH funded Tropical Disease Research Center in the Philippines. He currently serves on a WHO expert panel and was chairman of the Board of a large Gates Foundation project to deworm children in Sub Saharan Africa.
Peter Palese is Professor of Microbiology and Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York. His research is in the area of RNA-containing viruses with a special emphasis on influenza viruses. Specifically, he established the first genetic maps for influenza A, B, and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). He developed the field of reverse genetics for negative strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. An improvement of the technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent, but extinct, 1918 pandemic influenza virus. His recent work in collaboration with García-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host. At present, Palese’s group works with Adolfo García-Sastre and Florian Krammer on the development of a universal influenza virus vaccine. He was a recipient of the Robert Koch Prize in 2006, a recipient of the European Virology Award (EVA) in 2010, a recipient of the 2012 Sanofi-Institut Pasteur Award, and the awardee of the 2015 Beijerink Virology Prize of the Royal Netherlands Academy of Arts and Sciences. He is a Member of the National Academy of Sciences (2000), a Member of the National Academy of Medicine (2012) and a Fellow of the American Academy of Arts and Sciences (2014).
Pierluigi Petrone, CEO of Petrone Group.
Mr. Petrone is the export manager, shareholder and CEO of Petrone Group with head office in Naples, Italy. A holding company of approximately 30 firms, operating in the pharmaceutical, parapharmaceutical and health sectors. Petrone Group activities goes from pharmaceuticals distribution and warehousing , pharmaceuticals trading, training course to healthy sectors, real estate management, health consultancy and rehabilitation. Since 2007, Mr. Petrone is the Chairman of STM Group Logistica Integrata, Italian company among the top 5 active in the supply chain of drugs in particular but also of any other kind of goods. Since 2008, Mr. Petrone is a Business Relation Officer of Pierrel S.p.A., listed on the Italian Stock Exchange since May 2006, is today a full service global provider for life science, biopharma and pharmaceutical industries.
Since 1981, President of Scheer & Company, Inc., a company that has had a highly successful track record of building companies, along with providing corporate strategic and transactional advisory services in the life sciences industry. Much of his company-building activity emerged from a nearly 10-year affiliation with Oak Investment Partners, as part of their Health Care Investing Team.
He was a co-founder, and for 21 years, served as a member of the Board of Directors of Achillion Pharmaceuticals, Inc., a New Haven-based, publicly held, biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for complement-related diseases, which was acquired by Alexion in February, 2020.. From 2010 through the end of 2018, he served as the Company’s Chairman of the Board. He is also currently Chairman of the Board of the privately-held company, BiologicsMD, Inc.
He was involved in the founding and has been on the boards of a series of privately- and publicly-held companies, including Viropharma, Inc. (acquired by Shire), OraPharma (acquired by JNJ, now a unit of Valeant), and the original Esperion Therapeutics (served as Chairman, acquired by Pfizer). Mr. Scheer also served as a co-founder and Chairman of the Boards of Directors of Aegerion (now a part of Amryt), Optherion, Axerion (now ReNetx), ArRETT Neuroscience, and several others.
He currently leads the CT BioScience Coronavirus Task Force, and has been a Member of the Reopen CT Advisory Group.
Mr. Scheer holds an A.B. degree cum laude in Biochemical Sciences from Harvard College and an M.S. degree in Cell, Molecular and Developmental Biology from Yale University.
Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. has authored over 500 peer-reviewed papers and 7 books and holds 92 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 15 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies including Pharmasset, Inc. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 4 million lives worldwide. His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection.
Prof. Yiming Shao, MD and Ph.D., is the Chief Expert on AIDS in Chinese Centre for Disease Control and Prevention, Chair of the Academic Committee of the National Centre for AIDS/STD Control and Prevention. He started HIV/AIDS research in early 1980s and isolated China’s first HIV virus and developed initial confirmatory test for the country. As the funding director for national AIDS reference laboratory, he led a national expert task force to set up three national laboratory networks for HIV testing, molecular epidemiology survey and drug resistance surveillance in China. His lab mapped the origin and transmission of HIV-1 clades in China, identified 7 novel circulating recombinant forms (CRFs), isolated broader neutralizing monoclonal antibodies to various viral clades and conducted annual nationwide HIV drug resistance surveillance to support antiviral treatment in China.
His team developed HIV vaccine by re-designing HIV immunogen based on the first lentivirus vaccine (EIAV) and using replication competent vaccinia vector, derived from the Chinese small pox vaccine. The can induce good antibody and T cell responses and protect rhesus macaques against viral acquisition by SHIV challenges. Phase I and II clinical trials with the DNA vaccine priming and vaccinia boost have been conducted, generating good antibody response (100%) as well as T cell responses (>60%) in volunteers. Another phase IIa trial with a second vaccinia vector boost will be concluded soon. Then, they will move to phase IIb trials to test vaccine efficacy in MSM population in China. They will collaborate with US NIH to conduct a joint HIV vaccine clinical trial in China with Chinese DNA/vaccinia vaccine and NIH gp145 vaccine.
He has published more than 850 research papers in English and Chinese journals and got numerous scientific awards at Ministry and Municipal scientific awards and two National Science and Technology Progressive Awards. He served as the Chair of Chinese Virology Committee, vice Chair of Chinese Microbiology Society, adviser to the GCGH program of BMGF. He is serving on the WHO Vaccine Product Development for Vaccine Advisory Committee, HIV Cure Advisory Committee of International AIDS Society. He is the fellow of the American Academy of Microbiology and adjunct professors in Beijing university, Zhejiang university and Guangxi medical university in China.
Mr. Guangqi Tian is the President and Founder of Sino Invest Limited. He founded multiple companies in Harbin, Tianjin, and Beijing since 2005 and is owner or partial owner of businesses in Beijing, Tianjing, Hong Kong, US, Panama, and Dubai. He is engaged in international trade, investment and other businesses and has advised several Chinese state-owned companies on projects and ventures overseas and played instrumental roles in helping them win more than ten construction and investment contracts in Africa, Latin America, and Asia. Mr. Tian has invested in and managed commercial real estate projects in Tianjing. He has established and maintained good working relationships with different social entities in China, including, but not limited to, central and local governments and various business communities.
Dr. Pan Zheng was on faculty in a number of academic institutes including the Ohio State University, University of Michigan, Children’s National Medical Center and Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine. Dr. Zheng’s academic research focuses on immuno-oncology and inflammation. Dr. Zheng was trained in anatomic and clinical pathology and is a board-certified Physician with the American Board of Pathology.
Dr. Zheng co-founded OncoImmune, Inc. and served as its Chief Medical Officer since 2000 until its acquisition by Merck, Inc. Dr. Zheng designed and executed the clinical trials for the company, including most recently a Phase III clinical trial established strong therapeutic efficacy of CD24Fc for hospitalized severe and critical COVID-19 patients. Dr. Zheng continues to lead clinical development in OncoC4, Inc, which is devoted to improve safety and efficacy of cancer immunotherapy.